Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) EBITDA (2016 - 2025)

Traws Pharma's EBITDA history spans 14 years, with the latest figure at -$7.4 million for Q4 2025.

  • Quarterly results put EBITDA at -$7.4 million for Q4 2025, down 39.6% from a year ago — trailing twelve months through Dec 2025 was -$17.9 million (up 87.45% YoY), and the annual figure for FY2025 was -$17.9 million, up 87.45%.
  • EBITDA for Q4 2025 was -$7.4 million at Traws Pharma, down from -$4.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$1.2 million in Q2 2025 to a low of -$123.3 million in Q2 2024.
  • The 5-year median for EBITDA is -$4.9 million (2021), against an average of -$10.8 million.
  • The sharpest move saw EBITDA tumbled 2575.66% in 2024, then soared 98.99% in 2025.
  • Year by year, EBITDA stood at -$3.8 million in 2021, then plummeted by 52.38% to -$5.7 million in 2022, then rose by 22.18% to -$4.5 million in 2023, then fell by 18.29% to -$5.3 million in 2024, then crashed by 39.6% to -$7.4 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$7.4 million, -$4.1 million, and -$1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.